Kyle Leistikow began his research career at UW-Madison where he worked for three years under the guidance of Eric Johnson investigating the secretion and stability of Clostridial neurotoxins. He received his PhD from Marquette University under the guidance of Krassimira Hristova and Christopher Marshall where his work on bacterial communication systems led to the discovery of a novel antimicrobial compound capable of inhibiting clinical and agricultural MRSA infections.

Kyle currently leads a research team at Microbial Discovery Group that uses ecological, evolutionary, and computational approaches to understand and harness the ways in which commensal bacteria reduce disease and antimicrobial resistance evolution both in the host microbiome and in downstream environments. Over the last 10 years, he has established numerous collaborative relationships with both industrial and academic partners that have resulted in multiple patents, publications, and the adoption of One Health-based microbial surveillance programs.

• Why defining your problem is the first step before even thinking about AI.
• How clean, trustworthy data is more important than collecting more of it.
• Why not every challenge needs AI—sometimes a spreadsheet works just fine.
• What to consider before investing in tech: cost, value, and who it actually helps.
• Kyle’s “golden nugget”